Home » Topics » Disease categories and therapies » Hematologic

Hematologic
RSS

Merck & Co. designates thrombin inhibitor for clinical development

April 7, 1998

Early clinical trial evaluates orbofiban pharmacodynamics

April 7, 1998

FDA advisory committee will discuss Aggrastat NDA later this week

April 7, 1998

FDA approves another new indication for Lovenox

April 7, 1998

Antiplatelet and antithrombotic effects of FR-171113 in guinea pigs

April 6, 1998

Orally active thrombin inhibitor discovered at Pfizer shows good tolerance in phase I

April 6, 1998

Amidino derivatives for thrombosis reported by Astra

April 6, 1998

ART-123, a human recombinant thrombomodulin, demonstrates acceptable safety profile

April 6, 1998

FDA says Integrilin is approvable

April 3, 1998

Mechanism of vasorelaxant effects of HFV-1017C elucidated

April 2, 1998

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 6, 2026.
CINP 2026: Prenatal and adolescent stress shape brain vulnerability
BioWorld Science
Human biology is extraordinarily complex, and that sophistication emerges from the very beginning. During embryonic and fetal development, the organism’s...
Ontrack Therapeutics divulges compounds for neurodegenerative diseases
BioWorld Science
Ontrack Therapeutics Ltd. has reported new heterotricyclic compounds potentially useful for the treatment of neurodegenerative diseases.
Neurovalens granted FDA approval for PTSD therapy for US veterans
BioWorld
Veterans in the U.S. suffering from post-traumatic stress disorder (PTSD) now have access to Neurovalens Ltd.’s Modius Spero, a wearable neuromodulation device,...
Neuracle eyes Shanghai IPO as global BCI funding surges
BioWorld
Neuracle Medical Technology Co. Ltd. is seeking a Shanghai IPO that could make it China’s first publicly listed invasive brain-computer interface (BCI) company,...